Primary cutaneous T-cell non-Hodgkin lymphoma
MONDO:0000607A T-cell non-Hodgkin lymphoma arising from the skin. Representative examples include mycosis fungoides and primary cutaneous anaplastic large cell lymphoma.
Also known as: CTCL, PCTCL, T-cell non-Hodgkin's lymphoma of skin, T-cell non-Hodgkin's lymphoma of the skin, cutaneous T cell lymphoma, cutaneous T-cell lymphoma, cutaneous T-cell non-Hodgkin lymphoma, cutaneous T-cell non-Hodgkin's lymphoma
3205 clinical trials for this condition and its sub-types, 83 tagged with Primary cutaneous T-cell non-Hodgkin lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Primary cutaneous T-cell non-Hodgkin lymphoma
-
Mycosis fungoides 82 trials
-
Sezary syndrome 45 trials
-
Mycosis fungoides variant 1 trial · 3 incl. sub-types
3 sub-types
- Folliculotropic mycosis fungoides 3 trials
- Granulomatous slack skin disease 1 trial
- Localized pagetoid reticulosis 0 trials
-
Double-Drug attack on Hard-to-Treat lymphomas
Disease control Stopped earlyResearchers are testing whether combining two chemotherapy drugs, pralatrexate and romidepsin, is safe and effective for people with lymphoid cancers that have returned or stopped responding to treatment. The trial first finds the highest dose people can tolerate, then gives that…
Phase 1/2 • Sponsor: Jennifer Amengual • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Light-Activated gel shows promise for rare skin cancer
Disease control Stopped earlyThis Phase 3 trial tests a gel called HyBryte, which is activated by visible light, for treating cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. About 80 adults with early-stage CTCL will apply the gel or a placebo twice a week for 18 weeks, then receive light treat…
Phase 3 • Sponsor: Soligenix • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New lymphoma drug trial halted early
Disease control Stopped earlyThis study tested a new drug, PF-08046045, in 22 adults with advanced lymphomas (cancers of the immune system). The goal was to find a safe dose and check for side effects. The trial was stopped early, so results are limited.
Phase 1 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Experimental lymphoma drug ASTX660 tested in tiny, terminated trial
Disease control Stopped earlyThis early-phase trial tested the drug ASTX660 in just 8 people with T-cell lymphoma that had returned or not responded to prior treatments. The study aimed to find a safe dose and check for side effects, but it was stopped early. Because it was so small and incomplete, we cannot…
Phase 1/2 • Sponsor: Otsuka Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC